C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 14/52 (2006.01) A61K 38/00 (2006.01) C07K 14/54 (2006.01) C07K 14/715 (2006.01)
Patent
CA 2560525
The EBI3-p35 cytokine is shown for the first time to be capable of inhibiting immune responses mediated or controlled by T cells via an effect on suppressor T cells. This suggests that EBI3-p35 may be therapeutically effective in a variety of inflammatory and autoimmune conditions including arthritis, atherosclerosis, allograft rejection, and allergies such as asthma.
L'invention porte sur la cytokine EBI3-p35 capable, pour la première fois, d'inhiber les réponses immunitaires médiées ou contrôlées par les lymphocytes T par un effet sur les lymphocytes T de suppression. La cytokine EBI3-p35 peut être thérapeutiquement efficace contre plusieurs maladies inflammatoires et auto-immunes dont l'arthrite, l'athérosclérose, le rejet d'allogreffes, et d'allergies tel l'asthme.
Liew Foo Yew
Wei Xiao-Qing
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
The University Court Of The University Of Glasgow
LandOfFree
Immunosuppressive cytokine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunosuppressive cytokine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunosuppressive cytokine will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1655326